Carlo Tornatore1, J Theodore Phillips1, Omar Khan1, Aaron E Miller1, Mark Hughes1. 1. Medstar Georgetown University Hospital (CT), Washington, DC; Baylor Institute for Immunology Research (JTP), Dallas, TX; Wayne State University School of Medicine (OK), Detroit, MI; Icahn School of Medicine at Mount Sinai (AEM), New York, NY; and Infusion Communications (MH), Haddam, CT.
Abstract
PURPOSE OF REVIEW: To assess current practice patterns of US neurologists in patients with radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), and relapsing-remitting multiple sclerosis (RRMS) using case-based Web surveys. RECENT FINDINGS: We identified a total of 47 points of consensus (≥75% agreement) with regard to diagnosis, treatment, and monitoring of RIS, CIS, and RRMS. Current US treatment consensus patterns emphasize (1) MRI in multiple sclerosis (MS) diagnosis and subsequent treatment decisions, (2) treatment of early disease, (3) aggressive initial treatment of highly active MS, and (4) close patient monitoring for clinical response and adverse effects of disease-modifying drugs. SUMMARY: These findings may offer insights into harmonizing MS care and represent the first steps in potentially establishing a more uniform approach to the treatment of patients with MS in the United States without compromising the need for individual treatment for each patient.
PURPOSE OF REVIEW: To assess current practice patterns of US neurologists in patients with radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), and relapsing-remitting multiple sclerosis (RRMS) using case-based Web surveys. RECENT FINDINGS: We identified a total of 47 points of consensus (≥75% agreement) with regard to diagnosis, treatment, and monitoring of RIS, CIS, and RRMS. Current US treatment consensus patterns emphasize (1) MRI in multiple sclerosis (MS) diagnosis and subsequent treatment decisions, (2) treatment of early disease, (3) aggressive initial treatment of highly active MS, and (4) close patient monitoring for clinical response and adverse effects of disease-modifying drugs. SUMMARY: These findings may offer insights into harmonizing MS care and represent the first steps in potentially establishing a more uniform approach to the treatment of patients with MS in the United States without compromising the need for individual treatment for each patient.
Authors: Alberto Ascherio; Kassandra L Munger; Rick White; Karl Köchert; Kelly Claire Simon; Chris H Polman; Mark S Freedman; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Gilles Edan; Frederik Barkhof; Dirk Pleimes; Ernst-Wilhelm Radü; Rupert Sandbrink; Ludwig Kappos; Christoph Pohl Journal: JAMA Neurol Date: 2014-03 Impact factor: 18.302
Authors: Darin T Okuda; Aksel Siva; Orhun Kantarci; Matilde Inglese; Ilana Katz; Melih Tutuncu; B Mark Keegan; Stacy Donlon; Le H Hua; Angela Vidal-Jordana; Xavier Montalban; Alex Rovira; Mar Tintoré; Maria Pia Amato; Bruno Brochet; Jérôme de Seze; David Brassat; Patrick Vermersch; Nicola De Stefano; Maria Pia Sormani; Daniel Pelletier; Christine Lebrun Journal: PLoS One Date: 2014-03-05 Impact factor: 3.240
Authors: Bibiana Quirant-Sánchez; José V Hervás-García; Aina Teniente-Serra; Luis Brieva; Ester Moral-Torres; Antonio Cano; Elvira Munteis; María J Mansilla; Silvia Presas-Rodriguez; Juan Navarro-Barriuso; Cristina Ramo-Tello; Eva M Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2018-04-15 Impact factor: 5.243